Atezolizumab subcutaneous: patient satisfaction, effectiveness, and safety in routine care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non-interventional, multi-center, multicohort observational program that collects primary patient-reported data on satisfaction and health-related quality of life alongside routine effectiveness and safety outcomes for subcutaneous Atezolizumab. Participants receive Atezolizumab per local approved labeling for specific indications (various stages of NSCLC, ES-SCLC, or advanced/unresectable HCC) and continue standard clinical care. The study captures real-world experience across participating sites, with limits on prior intravenous Atezolizumab exposure and exclusion of concurrent systemic anticancer therapy at initiation. Data will be used to describe patient experience, HRQoL, and routine-use safety and effectiveness signals rather than to change treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:

  * Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC
  * Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated
  * Extensive-stage small cell lung cancer (ES-SCLC) not previously treated
  * Advanced or unresectable HCC not previously treated with systemic therapy
* Should not have received \> 4 prior cycles of IV Atezolizumab

Exclusion Criteria:

* Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling
* Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label
* Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program
* Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life

Where it's running

• Universitätsklinikum Krems
  Krems, Austria Recruiting
• Ordensklinikum Linz Elisabethinen
  Linz, Austria Recruiting
• Krankenhaus Nord - Klinik Floridsdorf
  Vienna, Austria Recruiting
• Klinikum Wels-Grieskirchen
  Wels, Austria Recruiting
• Chirec
  Auderghem, Belgium Recruiting
• AZ Sint Lucas (Sint Lucas)
  Ghent, Belgium Recruiting

+42 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• YSCH-01 alone or with atezolizumab for recurrent glioblastoma

  This will test whether YSCH-01 by itself or together with atezolizumab helps people with recurrent glioblastoma live longer.

  Recruiting Early Phase 1 Huashan Hospital · Shanghai, Shanghai Municipality · NCT07538128

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.